Biosimilars: What Will The Second Advisory Committee Tell Us?
This article was originally published in The Pink Sheet Daily
Executive Summary
Celltrion will have the most at stake next week, but future sponsors – and FDA itself – could learn a lot about how reviews of these new products work.
You may also be interested in...
FDA Sets New Goal For Biosimilar, Drug Promotion Guidances
Agency plans to issue 102 new and revised draft guidances this year, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and ANDA refuse-to-receive standards.
Zarxio Syringe’s Limitations May Delay Decision On Neupogen Interchangeability
FDA review documents for Sandoz’s filgrastim-sndz suggest that biosimilar sponsors need to consider how differences in delivery device from the reference product will play out under the 351(k) pathway, including whether new device designs and human factors data will be needed to secure interchangeability.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.